Long-term mental and brain health effects of COVID-19 from the Omicron strains among adult patients

Neuropsychiatric ‘long-COVID’ in adult patients (Phase 2)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11876145

Enrollment

1200

Registered

2023-04-19

Start date

2023-04-21

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

The method of assessment will be an online survey. The following data will be collected via the online survey: 1. Demographic data 2. Pre-COVID physical and mental health status 3. Socioeconomic profi

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. History of RAT or laboratory-confirmed SARS-CoV-2 infection of any level of severity 2. First confirmed SARS-CoV-2 infection happened in or after February 2022 OR First confirmed SARS-CoV-2 infection occurred more than 1 year ago 3. Aged between 18-65 years

Exclusion criteria

Exclusion criteria: Unable to give informed consent

Design outcomes

Primary

Measure	Time frame
Core neuropsychiatric symptom cluster(s) among COVID (Omicron) patients measured using self-reported questionnaires 1 year after the initial infection	—

Secondary

Measure	Time frame
1. Grey matter volume differences between COVID patients who suffer from core neuropsychiatric symptom cluster(s) and those who do not as measured by MRI, particularly in the olfactory cortex, limbic cortex, frontal cortex, and the brainstem, at 1 year after initial infection 2. Differences in white matter integrity between COVID patients who suffer from core neuropsychiatric symptom cluster(s) and those who do not as measured by MRI, particularly in the olfactory cortex, limbic cortex, frontal cortex, and the brainstem, at 1 year after initial infection 3. Differences in frequency of neuropsychiatric symptoms between COVID patients at 1 year after initial infection and controls who have never been infected, as measured by self-reported questionnaires 4. Differences in health-related quality of life (HRQOL) between COVID patients at 1 year after initial infection and controls who have never been infected, measured using self-reported questionnaires 5. Correlation of clinical characteristics of acute COVID, as retrieved from the electronic health record, with core neuropsychiatric symptom cluster(s) at 1 year post-infection, as measured by self-reporting questionnaire 6. Correlation of socioeconomic factors with core neuropsychiatric symptom cluster(s) at 1 year post-infection, as measured by self-reporting questionnaires 7. Correlation of vaccination status (type/number of doses) with core neuropsychiatric symptom cluster(s) at 1 year post-infection, as measured by self-reporting questionnaires 8. Differences in diffusivity and the index along the perivascular space (ALPS index) between COVID patients at 1 year after initial infection who suffer from core neuropsychiatric symptom cluster(s) and those who do not as measured by MRI 9. Differences in perfusion between COVID patients at 1 year after initial infection who suffer from core neuropsychiatric symptom cluster(s) and those who do not, as measured by MRI 10. Differences in frequency of new-onset psychiatric di	—

Measure

Time frame

1. Grey matter volume differences between COVID patients who suffer from core neuropsychiatric symptom cluster(s) and those who do not as measured by MRI, particularly in the olfactory cortex, limbic cortex, frontal cortex, and the brainstem, at 1 year after initial infection 2. Differences in white matter integrity between COVID patients who suffer from core neuropsychiatric symptom cluster(s) and those who do not as measured by MRI, particularly in the olfactory cortex, limbic cortex, frontal cortex, and the brainstem, at 1 year after initial infection 3. Differences in frequency of neuropsychiatric symptoms between COVID patients at 1 year after initial infection and controls who have never been infected, as measured by self-reported questionnaires 4. Differences in health-related quality of life (HRQOL) between COVID patients at 1 year after initial infection and controls who have never been infected, measured using self-reported questionnaires 5. Correlation of clinical characteristics of acute COVID, as retrieved from the electronic health record, with core neuropsychiatric symptom cluster(s) at 1 year post-infection, as measured by self-reporting questionnaire 6. Correlation of socioeconomic factors with core neuropsychiatric symptom cluster(s) at 1 year post-infection, as measured by self-reporting questionnaires 7. Correlation of vaccination status (type/number of doses) with core neuropsychiatric symptom cluster(s) at 1 year post-infection, as measured by self-reporting questionnaires 8. Differences in diffusivity and the index along the perivascular space (ALPS index) between COVID patients at 1 year after initial infection who suffer from core neuropsychiatric symptom cluster(s) and those who do not as measured by MRI 9. Differences in perfusion between COVID patients at 1 year after initial infection who suffer from core neuropsychiatric symptom cluster(s) and those who do not, as measured by MRI 10. Differences in frequency of new-onset psychiatric di

—

Countries

Hong Kong

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 30, 2026